ALK-Abello A/S/€ALKB

1D1W1MYTD1Y5YMAX

About ALK-Abello A/S

ALK-Abelló A/S is a Danish company specializing in the development and production of allergy immunotherapy products. The company operates within the pharmaceutical industry, providing allergy treatments that include tablets, injections, and drops. Notably, ALK-Abelló focuses on allergy immunotherapy for respiratory allergies, such as allergies to grass, tree pollen, house dust mites, and animal dander. Headquartered in Hørsholm, Denmark, ALK-Abelló serves a global market with a significant presence in Europe and North America. The company's strategic focus on research and development in allergy solutions and its specialized product portfolio underscore its commitment to addressing a critical niche in the healthcare sector.
Ticker
€ALKB
Sector
Health
Primary listing
XGAT
Employees
2,773
Headquarters
Horsholm, Denmark
Website
www.alk.net

ALK-Abello A/S Metrics

BasicAdvanced
€5.9B
32.56
€0.82
0.71
€0.21
0.81%

Bulls say / Bears say

ALK delivered 18% revenue growth in both Q1 and Q2, while EBIT rose 22% and 19% respectively. Management raised 2026 revenue guidance to 14–16% growth and still expects an EBIT margin of about 26%. (Inderes, ALK)
Tablet sales rose 22% in Q2, helped by paediatric expansion, while NICE recommended ALK’s tree-pollen and house-dust-mite tablets for eligible children in the UK. These decisions broaden access and can expand the prescriber and patient base. (Inderes, BioSpace)
The peanut allergy tablet produced a positive phase 2 result and is planned to enter phase 3 in late 2026, subject to regulatory feedback. At the same time, neffy has gained approvals and launched in additional markets, adding longer-term growth options beyond respiratory-allergy tablets. (ALK, GlobeNewswire)
Germany will raise the mandatory rebate on prescription medicines from January 2027, and Germany represented about a quarter of ALK’s 2025 revenue. This creates a clear risk to pricing and margins in its largest market. (ROIC AI, Inderes)
ALK’s Q2 EBIT margin stayed at 25% even as gross margins improved, because sales, marketing, research and development and capacity costs rose sharply. Continued reinvestment may limit profit growth despite strong revenue growth. (ROIC AI, Inderes)
The neffy launch remains at an early stage, with revenue still modest and the UK rollout slowed by formulary and administrative delays. This leaves the expected contribution from the anaphylaxis franchise dependent on difficult market-access execution. (ROIC AI, Inderes)
Data summarised monthly by Lightyear AI. Last updated on 16 Sept 2026.

Funds containing ALK-Abello A/S

AllGBPEUR
Funds
Fund name
Fund size
€ALKB weighting
Vanguard ESG Global All Cap£V3AB
£905M0.00%
Vanguard ESG Global All Cap€V3AA
€1.1B0.00%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.